Pharmacokinetics of brotizolam in renal failure.
Kinetics of brotizolam (0.25 mg) were studied in patients with different degrees of renal failure after single and repeated oral ingestion. Serum levels were analysed by radio-immunoassay. Patients were divided into three groups according to their renal function, i.e. creatinine clearance values of 45-80, 15-45, or less than 15 ml/min. The mean elimination half-life was 6.9-8.15 h, with a considerable variation of the peak concentration and elimination half-life in slight to moderate renal failure. There was no delay in elimination in severe renal failure and there was no drug accumulation. No dose adjustment is necessary for brotizolam in renal failure.
D000328:Adult; D001381:Azepines / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000378:metabolism*; D007668:Kidney / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D007677:Kidney Function Tests; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay
D001381:Azepines; D006993:Hypnotics and Sedatives; C020960:brotizolam